ArticleeLife2021
Microbiome-pathogen interactions drive epidemiological dynamics of antibiotic resistance: A modeling study applied to nosocomial pathogen control.
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Mapping the landscape of mathematical models for antimicrobial resistance: a scoping review.BMC public health · 2026Article
- Modelling the role of the microbiome in antimicrobial resistance across scales.Nature microbiology · 2026Review
- Emerging Microbiome-Based Therapies for Skin Infections: From Probiotics and Prebiotics to Synthetic Microbiome Engineering.Infection and drug resistance · 2026Review
- Dynamic contagion potential framework for optimizing infection control in healthcare.Frontiers in public health · 2025Article
- Excessive active pharmaceutical ingredients in substandard and falsified drugs should also raise concerns in low-income countries.Journal of global health · 2024Review
- Overcoming challenges in the economic evaluation of interventions to optimise antibiotic use.Communications medicine · 2024Review
- Antimicrobial Resistance as Risk Factor for Recurrent Bacteremia after Staphylococcus aureus, Escherichia coli, or Klebsiella spp. Community-Onset Bacteremia.Emerging infectious diseases · 2024Article
- Within-Host Mathematical Models of Antibiotic Resistance.Methods in molecular biology (Clifton, N.J.) · 2024Article
- The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance.Nature communications · 2023Review
- Collateral impacts of pandemic COVID-19 drive the nosocomial spread of antibiotic resistance: A modelling study.PLoS medicine · 2023Article
- Microbial interactions and the homeostasis of the gut microbiome: the role ofMicrobiome research reports · 2023Review
- The impacts of viral infection and subsequent antimicrobials on the microbiome-resistome of growing pigs.Microbiome · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The human microbiome can protect against colonization with pathogenic antibiotic-resistant bacteria (ARB), but its impacts on the spread of antibiotic resistance are poorly understood. We propose a mathematical modeling framework for ARB epidemiology formalizing within-host ARB-microbiome competition, and impacts of antibiotic consumption on microbiome function. Applied to the healthcare setting, we demonstrate a trade-off whereby antibiotics simultaneously clear bacterial pathogens and increase host susceptibility to their colonization, and compare this framework with a traditional strain-based approach. At the population level, microbiome interactions drive ARB incidence, but not resistance rates, reflecting distinct epidemiological relevance of different forces of competition. Simulating a range of public health interventions (contact precautions, antibiotic stewardship, microbiome recovery therapy) and pathogens (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.